Helena F. Florindo

PhD (2008) in Pharmacy (Pharmaceutical Technology), Universidade de Lisboa

Assistant Professor, Pharmaceutics and Pharmaceutical Technology

Faculdade de Farmácia, Universidade de Lisboa — Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal

T (+351) 217 946 400
F (+351) 217 946 470
Researcher ID E-7913-2012
Group Researcher ID B-4826-2014
Scopus Author ID 24402599300

Research Interests

Florindo’s research is focused on the development of multivalent nanotechnology-based systems to modulate the recognition, capture, processing and presentation of cancer antigens by dendritic cells. It includes the in vitro and in vivo studies of the anti-tumor effects induced by the combination of these nanovaccines with nanotherapeutics designed to modulate the function and activation of other key cells within tumor site, such as T cells, myeloid-derived cells and tumor cells.

Selected Publications

Zupančič E, Curato C, Paisana M, Rodrigues C, Porat Z, Viana AS, Afonso CA, Pinto J, Moreira JN, Gaspar R, Satchi-Fainaro R, Jung S, Florindo HF. Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming. J Control Release 2017; 28: 182-195.

Silva AL, Peres C, Conniot J, Matos AI, Moura L, Carreira B, Sainz V, Scomparin A, Satchi-Fainaro R, Préat V, Florindo HF. Nanoparticle impact on innate immune cell pattern-recognition receptors and inflammasomes activation. Semin Immunol 2017; 30: 3-24

Santos FMF, Matos AI, Ventura AE, Gonçalves J, Veiros LF, Florindo HF, Gois PMP. Modular Assembly of Reversible Multivalent Targeting Drug Conjugates. Angewandte Chemie 2017; 56: 9346-9350.

Silva JM, Zupancic E, Vandermeulen G, Oliveira V, Salgado A, Videira M, Gaspar M, Graça L, Préat V, Florindo HF. In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumour immune responses in a melanoma model. J Control Release 2015; 198C: 91-103.

Silva JM, Videira M, Gaspar R, Préat V, Florindo HF. Immune System Targeting by Nanoparticles for Cancer Vaccines. J Control Release 2013; 168: 179-199.